Impact Life Sciences – VentureCapital Magazine

Funding opens up important opportunities

We are pleased to share that Dr. Rosi Hermann, was featured in the latest issue of VC Impact Life Sciences. In the article "Global Perspectives: Germany, Europe, and the World," she discusses how Germany's research allowance opens up funding opportunities for life sciences companies of all sizes – from start-ups to large corporations.

To the article: VentureCapital Magazin 06/2026

Alongside this, there is a frequently overlooked source of hope: Germany's funding ecosystem. The myth persists that funding is complicated and only available to large companies. However, Dr Rosemarie Hermann, from funding consultancy Fundess, based in Munich and Frankfurt am Main, disagrees: 'The research allowance is open to companies of all sizes, from start-ups to large corporations.' In the life sciences sector, she finds that companies often view their development work as an integral part of their business. 'In fact, these activities are eligible for funding, offering considerable financial potential,' she says. One example is a packaging specialist for cytostatic drugs who received funding for their highly automated solutions. A generics manufacturer was also funded – not for a new active ingredient, but for its digital ADHD care concept. 'Some people are surprised to realise what can be considered research in this context,' says Hermann. She does not view funding as a stopgap measure, but rather as a strategic tool. 'It helps to reduce technological risks, build new partnerships, and implement development projects that would be much more difficult to realise independently – all of which can mean the difference between failure and scaling up.'

To our profile: VentureCapital Magazine 06/2026